Pfizer and BioNTech’s corona vaccine is 95 percent effective. This is evident from the full study results now that the clinical trials were completed, the pharmaceutical company Pfizer itself reported on Wednesday.
–
“We are proud to partner with BioNTech to announce that the Phase 3 trial of our COVID-19 vaccine candidate has met all primary efficacy endpoints,” Pfizer said on Twitter. The vaccine candidate, officially named ‘BNT162b2’, was 95 percent effective from 28 days after the first dose. 170 confirmed cases of COVID-19 were evaluated, with 162 cases observed in the placebo group versus 8 in the vaccination group.
The effectiveness rate is higher than that of the partial results published last week. Then the results showed “over 90 percent” efficiency.
Pfizer will submit the results for approval to the US drug watchdog FDA “within days”. According to the pharmaceutical company, the candidate vaccine has reached the safety requirements required for an ‘EUA’, an emergency permit. “To date, no serious safety concerns regarding the vaccine candidate have been reported,” it said on Twitter. The data on the efficacy and safety of the study will eventually also be submitted to a scientific journal for peer review.
– .
